Archive for the ‘Cholesterol’ Category

Tepnel Announces New DNA Test For Early Detection Of Familial Hypercholesterolaemia

Friday, August 29th, 2008
Just ahead of the expected release of clinical practice guidelines on Familial Hypercholesterolaemia (FH) by the influential National Institute for Clinical Excellence (NICE), Tepnel Life Sciences PLC (AIM: TED) today announced the launch of a DNA test for the early detection of FH, a genetic conditi

New NICE Guidelines Are Set To Reduce Premature Deaths In People Who Have Inherited High Cholesterol

Thursday, August 28th, 2008
The National Institute for Health and Clinical Excellence (NICE) and the National Collaborating Centre for Primary Care have today (27 August 2008) published a guideline on the care and treatment of adults and children/young people with familial hypercholesterolaemia (FH), a type of high cholesterol that is caused by an inherited genetic mutation.

New Pre-Clinical Research On RNAi-Mediated Silencing Of PCSK9, A Genetically Validated Regulator Of LDL Metabolism

Thursday, August 14th, 2008
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced that new pre-clinical data from its hypercholesterolemia program was published in Proceedings of the National Academy of Sciences (Frank-Kamenetsky, M., et al (August 11, 2008) Proc. Natl Acad. Sci. USA, 10.1073/pnas.0805434105).

Designer RNA Fights High Cholesterol, Researchers Find

Tuesday, August 12th, 2008
Small, specially designed bits of ribonucleic acid (RNA) can interfere with cholesterol metabolism, reducing harmful cholesterol by two-thirds in pre-clinical tests, according to a new study by researchers at UT Southwestern Medical Center in collaboration with Alnylam Pharmaceuticals and the Massachusetts Institute of Technology.

Genzyme And Isis Begin Second Phase 3 Trial Of Mipomersen

Thursday, August 7th, 2008
Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that they have begun a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH), a genetic disorder that causes exceptionally high levels of LDL cholesterol.

Lowering Cholesterol Early In Life Could Save Lives - Intervention Should Begin In Childhood, Say UC San Diego Scientists

Tuesday, August 5th, 2008
With heart disease maintaining top billing as the leading cause of death in the United States, a team of University of California, San Diego School of Medicine physician-researchers is proposing that aggressive intervention to lower cholesterol levels as early as childhood is the best approach available today to reducing the incidence of coronary heart disease.